A retrospective analysis of recurrent pediatric ependymoma reveals
extremely poor survival ind ineffectiveness of current treatments across
central nervous locations and molecular subgroups.
- Trggve Lundar
, - Bernt Due-Tønnesen,
- Radek Fric
26 May 2021Submitted to Pediatric Blood & Cancer 26 May 2021Submission Checks Completed
26 May 2021Assigned to Editor
03 Jun 2021Review(s) Completed, Editorial Evaluation Pending
03 Jun 2021Editorial Decision: Revise Minor
03 Jun 20211st Revision Received
03 Jun 2021Submission Checks Completed
03 Jun 2021Assigned to Editor
04 Jun 2021Review(s) Completed, Editorial Evaluation Pending
05 Jun 2021Editorial Decision: Accept
